We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PSKY
926
Paramount Skydance Corp
PSKY
$8.9B
| $234K | ﹤0.01% |
17,483
| – | – |
|
927
Natera
NTRA
$36.4B
| $233K | ﹤0.01% |
+1,016
| New | +$212K |
|
928
DaVita
DVA
$15.5B
| $230K | ﹤0.01% |
2,024
-9,522
| -82% | -$1.16M |
|
929
SoFi Technologies
SOFI
$19.6B
| $228K | ﹤0.01% |
8,728
+173
| +2% | +$4.82K |
|
|
AMRZ
930
Amrize Ltd
AMRZ
$27.4B
| $218K | ﹤0.01% |
+4,025
| New | +$205K |
|
|
HEPS
931
D-Market Electronic Services & Trading
HEPS
$1.02B
| $191K | ﹤0.01% |
+77,099
| New | +$191K |
|
|
BDN
932
Brandywine Realty Trust
BDN
$509M
| $162K | ﹤0.01% |
55,420
-46,660
| -46% | -$159K |
|
933
Uranium Energy
UEC
$4.47B
| $149K | ﹤0.01% |
12,788
+1,592
| +14% | +$20.9K |
|
934
ReNew
RNW
$2.18B
| $132K | ﹤0.01% |
23,334
+3,000
| +15% | +$21.7K |
|
|
FINV
935
FinVolution Group
FINV
$1.17B
| $119K | ﹤0.01% |
22,715
| – | – |
|
936
NIO
NIO
$11.9B
| $65.5K | ﹤0.01% |
12,837
-1,642
| -11% | -$10.1K |
|
937
Arbutus Biopharma
ABUS
$847M
| – | – |
-799,979
| Closed | -$3.63M |
|
938
Albertsons Companies
ACI
$5.91B
| – | – |
-21,012
| Closed | -$367K |
|
939
Adecoagro
AGRO
$1.4B
| – | – |
-83,776
| Closed | -$657K |
|
|
AKRO
940
DELISTED
Akero Therapeutics
AKRO
| – | – |
-502,913
| Closed | -$23.9M |
|
941
Alkermes
ALKS
$8.11B
| – | – |
-146,224
| Closed | -$4.39M |
|
942
Ardelyx
ARDX
$1.24B
| – | – |
-865,596
| Closed | -$4.77M |
|
943
ASE Group
ASX
$68.3B
| – | – |
-21,491
| Closed | -$237K |
|
|
BCIM
944
DELISTED
abrdn Bloomberg Industrial Metals Strategy K-1 Free ETF
BCIM
| – | – |
-365,025
| Closed | -$7.9M |
|
|
945
BioMarin Pharmaceuticals
BMRN
$11.9B
| – | – |
-902,751
| Closed | -$48.9M |
|
946
Bentley Systems
BSY
$11.2B
| – | – |
-4,353
| Closed | -$224K |
|
947
Crown Holdings
CCK
$13B
| – | – |
-7,322
| Closed | -$707K |
|
|
CDTX
948
DELISTED
Cidara Therapeutics
CDTX
| – | – |
-177,523
| Closed | -$17M |
|
|
CHCT
949
Community Healthcare Trust
CHCT
$536M
| – | – |
-14,900
| Closed | -$224K |
|
950
CI&T Inc
CINT
$423M
| – | – |
-305,687
| Closed | -$1.61M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.